IDEAYA Appoints Stu Dorman as Chief Commercial Officer: https://lnkd.in/gNPJMtXM
IDEAYA Biosciences
生物技术研究
South San Francisco，California 14,409 位关注者
Synthetic lethality precision medicine oncology company pursuing– an emerging class of precision medicine targets.
关于我们
IDEAYA is an oncology-focused precision medicine company. Our teams are committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. We are advancing therapeutics that have the potential to be first-in-class and/or best-in-class, with a primary focus in synthetic lethality – an emerging class of precision medicine targets. IDEAYA is headquartered in South San Francisco, California.
- 网站
-
https://www.ideayabio.com
IDEAYA Biosciences的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- South San Francisco，California
- 类型
- 上市公司
- 创立
- 2015
- 领域
- Synthetic Lethality和Precision Medicine
地点
-
主要
获取路线
7000 Shoreline Court
350
US，California，South San Francisco，94080
IDEAYA Biosciences员工
动态
-
IDEAYA Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day: https://lnkd.in/gwhju2jY
-
IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen: https://lnkd.in/gczmvjPy
-
-
IDEAYA Reports Third Quarter 2024 Financial Results and Provides Business Update: https://lnkd.in/gahGNabU
IDEAYA Reports Third Quarter 2024 Financial Results and Provides Business Update
media.ideayabio.com
-
IDEAYA Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4): https://lnkd.in/gAtmfgmN
-
IDEAYA Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors: https://lnkd.in/gWivHTgt
-
-
IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024: https://lnkd.in/gHxDPThd
IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024
media.ideayabio.com
-
IDEAYA Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium: https://lnkd.in/ggn67Fgv
IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium
media.ideayabio.com
-
IDEAYA Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4): https://lnkd.in/gKBVpvZn
-
IDEAYA Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma: https://lnkd.in/gaCe_FAU
-